Synact changes strategy in phase 1 with its arthritis hope

Danish biotech company Synact Pharma did not get the results the company expected with its main asset AP1189 in a phase 1 study. The company is now trying again with a different delivery method, which will delay the drug's development up to a year.

Synact Pharma's CFO Henrik Stage (left), CEO Jeppe Øvlesen (mid) and CSO Thomas Jonassen (right) Photo: Synact Pharma

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles